Integrated needle-free injection and sensing using opto-microfluidics
iSENS is developing BoldJet, a portable needle-free injector using thermocavitation microjets for precise, safe, and environmentally friendly medication delivery, enhancing patient compliance and healthcare outcomes.
Projectdetails
Introduction
Needle-based injections have revolutionised healthcare by providing an efficient delivery method for medications, such as vaccines. However, there are significant drawbacks associated with using needles on a societal, environmental, and technological level.
Challenges of Needle Use
- Needle Phobia and Infection Risks: Needle phobia and infection risks can significantly impact patient compliance and safety with medical treatments.
- Environmental Contamination: Millions of used needles contaminate the environment every day.
- Injection Effectiveness: The effectiveness of certain drugs increases when injected intradermally, but targeting the dermis is challenging.
Project Overview
With iSENS, we want to revolutionise the experience of people who receive and perform frequent injections. To this end, we are developing and commercialising a portable and needle-free injector called BoldJet.
Technological Breakthroughs
Our technological breakthrough is threefold:
-
Needle-Free Injection Breakthrough: We introduce an innovative needle-free injection technology, globally pioneering the use of thermocavitation microjets. Our system excels in the precise and consistent delivery of liquids into the skin's superficial layers, surpassing current state-of-the-art methods.
-
Smart Sensing Capability: The BoldJet device will incorporate cutting-edge sensing technology, enabling it to assess the unique properties of the patient's skin before each injection. This breakthrough allows for semi-automatic calibration, tailoring the injection parameters to the specific skin type and treatment area.
-
Real-Time Monitoring and Precision: BoldJet goes beyond conventional methods by offering real-time monitoring of injection depth and volume. This feature guarantees that each dose is administered accurately and consistently.
Conclusion
With our triple technology platform, we will offer safer, more effective, and minimally invasive injections that do not contaminate our environment. This patient-friendly technology will result in a positive effect on society, allowing millions of people to receive better and more personalised healthcare.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.499.999 |
Totale projectbegroting | € 2.512.500 |
Tijdlijn
Startdatum | 1-7-2024 |
Einddatum | 30-6-2027 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- FLOWBEAMS BVpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Transition
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Skin micro-injectorBold-Jet aims to revolutionize needle-free injections with a microjet device that enhances safety, minimizes invasiveness, and improves patient adherence to treatments. | ERC POC | € 150.000 | 2022 | Details |
Overcoming limits for pre-clinical small volume liquid delivery into skin and inflammation quantificationThis project aims to validate the BuBble Gun injection method using Skin-On-Chip technology for localized drug testing in chronic skin diseases, paving the way for innovative treatment delivery. | ERC POC | € 150.000 | 2025 | Details |
AmbiJet: the world’s first and only highly effective plasma-based solution for Europe’s 16 Million periimplantitis patients urgently needing help to avoid losing their dental implantAmbiJet is a groundbreaking plasma-based technology that effectively eliminates bacteria on dental implants, preventing reinfection and promoting better oral and overall health. | EIC Accelerator | € 1.389.062 | 2022 | Details |
NEW PRODUCTION METHOD OF INJECTABLE MICROCAPSULES FOR PULSATILE VACCINE DELIVERYIamFluidics onderzoekt de haalbaarheid van 'in-air microfluidics' voor het produceren van polylactic acid microcapsules voor gecontroleerde vaccinafgifte, met als doel een kosteneffectieve, pulsatile injectieoplossing. | MIT Haalbaarheid | € 20.000 | 2022 | Details |
Skin micro-injector
Bold-Jet aims to revolutionize needle-free injections with a microjet device that enhances safety, minimizes invasiveness, and improves patient adherence to treatments.
Overcoming limits for pre-clinical small volume liquid delivery into skin and inflammation quantification
This project aims to validate the BuBble Gun injection method using Skin-On-Chip technology for localized drug testing in chronic skin diseases, paving the way for innovative treatment delivery.
AmbiJet: the world’s first and only highly effective plasma-based solution for Europe’s 16 Million periimplantitis patients urgently needing help to avoid losing their dental implant
AmbiJet is a groundbreaking plasma-based technology that effectively eliminates bacteria on dental implants, preventing reinfection and promoting better oral and overall health.
NEW PRODUCTION METHOD OF INJECTABLE MICROCAPSULES FOR PULSATILE VACCINE DELIVERY
IamFluidics onderzoekt de haalbaarheid van 'in-air microfluidics' voor het produceren van polylactic acid microcapsules voor gecontroleerde vaccinafgifte, met als doel een kosteneffectieve, pulsatile injectieoplossing.